CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReNeuron Group Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReNeuron Group Plc
Pencoed Business Park
Phone: +44 2038198400p:+44 2038198400 BRIDGEND, CF35 5HY  United Kingdom Fax: +44 1483534864f:+44 1483534864
Placed into Administration on 3/20/2024
On 3/20/2024, ReNeuron Group Plc was placed into Administration along with its UK subsidiaries: ReNeuron Holdings Limited, ReNeuron Limited, and ReNeuron (UK) Limited, in the High Court of Justice Business and Property Courts of England and Wales. Mark Smith and Stephen Cork of Cork Gully LLP were appointed as the Administrators.
This company is no longer actively traded on any major stock exchange.
Business Summary
ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Iain G.Ross 1/3/2023 7/2/2021
Chief Operations Officer SuzanneHancock 9/14/2022 7/1/2020
Chief Scientific Officer RandolphCorteling 9/14/2022 4/1/2015
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ReNeuron Ireland Limited The Black Church, St. Mary's Place Dublin Ireland
ReNeuron Limited C/O Cork Gully LLP, 40 Villiers Street London United Kingdom
ReNeuron (UK) Limited Pencoed Business Park, Pencoed Bridgend Wales United Kingdom
ReNeuron Holdings Limited Pencoed Business Park, Pencoed Bridgend Wales United Kingdom

Business Names
Business Name
ReNeuron Holdings Limited
ReNeuron Holdings plc
ReNeuron Ireland Limited
RENEURON LIMITED

General Information
Outstanding Shares: 57,173,760 (As of 2/29/2024)
Shareholders: 31,374
Stock Exchange: LON
Fax Number: +44 1483534864


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024